PARP1 and cancer: However, in BRCA competent cancers, characterized by a possibly reduced STING-associated IFN type I pathway, where DNA lesions induced by PARP blockade could be inadequate, the use of a STING agonist combined with IC blockade has been suggested as an alternative potential therapeutic combination approach [87,101].